It is identified in approximately 3% to 7% of NSCLC patients,[1,2] and is highly sensitive to ALK tyrosine kinase inhibitors (TKIs) such as crizotinib, alectinib, ceritinib, brigatinib.[3,4] In the era of cancer precision therapy, with the continuous optimization and update of gene sequencing technology, more and more atypical ALK fusion genes have been detected. The gene discussed is ALK; the disease is cancer.